Citadel Advisors
VIVE

Citadel Advisors’s VIVEVE MED INC VIVE Stock Holding History

Citadel Advisors’s Portfolio VIVE Stock Details VIVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-25,740
Closed -$17K – 14084
2022
Q2 		$17K Buy
+25,740
New +$21.9K ﹤0.01% 12470
2022
Q1 		– Sell
-27,901
Closed -$32K – 15059
2021
Q4 		$32K Buy
+27,901
New +$51.2K ﹤0.01% 13460
2021
Q3 		– Sell
-17,867
Closed -$53K – 15034
2021
Q2 		$53K Sell
17,867
-11,640
-39% -$32.7K ﹤0.01% 13319
2021
Q1 		$90K Buy
+29,507
New +$108K ﹤0.01% 12563
2019
Q2 		– Sell
-16
Closed -$15K – 10088
2019
Q1 		$15K Sell
16
-5
-24% -$5.3K ﹤0.01% 9114
2018
Q4 		$22K Buy
+21
New +$50.4K ﹤0.01% 8718

Other funds holding VIVE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's VIVE Position: Q3 2022 in Review

Citadel Advisors sold out of VIVEVE MED INC (VIVE) in Q3 2022, closing a stake of 25,740 shares — an estimated $17K sold.

Citadel Advisors first reported a position in VIVE in Q4 2018 and held it in 6 quarters. The position peaked at $90K in Q1 2021. 15 funds tracked by Wall St. Rank hold VIVE as of Q3 2022.

  • Citadel Advisors reported no remaining VIVEVE MED INC position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 25,740 VIVEVE MED INC shares in Q3 2022, an estimated $17K.
  • Citadel Advisors first reported a position in VIVEVE MED INC in Q4 2018 and held it in 6 quarters.
  • Citadel Advisors's VIVEVE MED INC position peaked at $90K in Q1 2021.
  • 15 funds tracked by Wall St. Rank held VIVEVE MED INC as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.